Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Clinical Genitourinary Cancer
|
December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance
David D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
European Urology
|
December 18, 2018
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer
David D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 8, 2025
Implementing a context-augmented large language model to guide precision cancer medicine
Hyeji Jun, Yutaro Tanaka, Shreya Johri, et al.
Urologic Oncology
|
July 14, 2020
Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer
David D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 30, 2023
Assessing the Feasibility of Using Artificial Intelligence-Segmented Dominant Intraprostatic Lesion for Focal Intraprostatic Boost With External Beam Radiation Therapy
James M G Tsui, Christopher E Kehayias, Jonathan E Leeman, et al.
Radiation Oncology (London, England)
|
August 18, 2020
Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer
David D Yang, Daniela L Buscariollo, Angel M Cronin, et al.
Cancer
|
December 13, 2017
Travel distance and stereotactic body radiotherapy for localized prostate cancer
Brandon A Mahal, Yu-Wei Chen, Roshan V Sethi, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 3, 2017
National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer
David D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
European Urology Focus
|
July 30, 2017
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer
David D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Biorxiv : the Preprint Server for Biology
|
June 6, 2025
Immune Spatial Organization Predicts Metastasis Risk in Aggressive Localized Prostate Cancer
David D Yang, Aya Abdelnaser, Jeremiah Wala, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Clinical Genitourinary Cancer
|
December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance
David D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
European Urology
|
December 18, 2018
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer
David D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 8, 2025
Implementing a context-augmented large language model to guide precision cancer medicine
Hyeji Jun, Yutaro Tanaka, Shreya Johri, et al.
Urologic Oncology
|
July 14, 2020
Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer
David D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 30, 2023
Assessing the Feasibility of Using Artificial Intelligence-Segmented Dominant Intraprostatic Lesion for Focal Intraprostatic Boost With External Beam Radiation Therapy
James M G Tsui, Christopher E Kehayias, Jonathan E Leeman, et al.
Radiation Oncology (London, England)
|
August 18, 2020
Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer
David D Yang, Daniela L Buscariollo, Angel M Cronin, et al.
Cancer
|
December 13, 2017
Travel distance and stereotactic body radiotherapy for localized prostate cancer
Brandon A Mahal, Yu-Wei Chen, Roshan V Sethi, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 3, 2017
National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer
David D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
European Urology Focus
|
July 30, 2017
Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer
David D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Biorxiv : the Preprint Server for Biology
|
June 6, 2025
Immune Spatial Organization Predicts Metastasis Risk in Aggressive Localized Prostate Cancer
David D Yang, Aya Abdelnaser, Jeremiah Wala, et al.
Page
of 5